A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab
Phase 1
168
about 2.9 years
18+
9 sites in CA, FL, OH +3
About this study
Researchers are testing different doses of a drug (ONM-501) given directly into tumors, alone or with another medication (Cemiplimab), to see what the highest dose that can be safely used, the lowest effective dose, or a recommended dose for expansion is in people with advanced solid tumors and lymphomas. The trial will last about 1051 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cemiplimab
- 2.Take ONM-501
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cemiplimab
Primary: Dose Escalation and Expansion Phases: Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs), Dose Escalation and Expansion Phases: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity
Secondary: Dose Escalation and Expansion Phases: Cmax, Dose Escalation and Expansion Phases: Tmax, Expansion Phase Only: Duration of Response (DOR), Expansion Phase Only: Objective Response Rate (ORR), Expansion Phase Only: Overall Survival (OS), Expansion Phase Only: Progression-Free Survival (PFS)
Oncology